Harvard Bioscience (HBIO) 10-K 9 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 01, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001123494
Entity Registrant Name	HARVARD BIOSCIENCE INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-33957
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3306140
Entity Address, Address Line One	84 October Hill Road
Entity Address, City or Town	Holliston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01746
City Area Code	508
Local Phone Number	893-8999
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HBIO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 141,800,000
Entity Common Stock, Shares Outstanding		42,190,043
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Hartford, Connecticut

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,508	$ 7,821
Accounts receivable, net	16,705	21,834
Inventories	26,439	27,587
Other current assets	3,472	4,341
Total current assets	51,124	61,583
Property, plant and equipment, net	3,366	3,415
Operating lease right-of-use assets	5,816	6,897
Goodwill	56,260	57,689
Intangible assets, net	21,014	27,385
Other long-term assets	7,780	5,375
Total assets	145,360	162,344
Current liabilities:
Current portion of long-term debt	3,811	3,235
Current portion, operating lease liabilities	2,135	2,142
Accounts payable	6,447	4,911
Deferred revenue	3,370	4,266
Other current liabilities	7,486	10,762
Total current liabilities	23,249	25,316
Long-term debt, net	43,013	45,095
Deferred tax liability	590	1,558
Operating lease liabilities	5,282	6,488
Other long-term liabilities	1,006	486
Total liabilities	73,140	78,943
Commitments and contingencies - Note 14
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 42,081,707 shares issued and outstanding at December 31, 2022; 41,142,876 shares issued and outstanding at December 31, 2021	454	452
Additional paid-in-capital	229,008	225,650
Accumulated deficit	(142,190)	(132,674)
Accumulated other comprehensive loss	(15,052)	(10,027)
Total stockholders' equity	72,220	83,401
Total liabilities and stockholders' equity	$ 145,360	$ 162,344

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	42,081,707	41,142,876
Common stock, shares outstanding (in shares)	42,081,707	41,142,876

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues	$ 113,335	$ 118,904
Cost of revenues	52,516	51,252
Gross profit	60,819	67,652
Sales and marketing expenses	25,041	24,642
General and administrative expenses	24,493	24,305
Research and development expenses	12,329	10,799
Amortization of intangible assets	6,122	5,840
Settlement of litigation, net - Note 15	(233)	0
Total operating expenses	67,752	65,586
Operating (loss) income	6,933	(2,066)
Other (expense) income:
Interest expense	(2,548)	(1,540)
Other income (expense), net	302	(666)
Total other expense	(2,246)	(2,206)
Loss before income taxes	(9,179)	(140)
Total income tax expense (benefit)	337	148
Net loss	$ (9,516)	$ (288)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.23)	$ (0.01)
Weighted-average common shares:
Basic and diluted (in shares)	41,413	40,343

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (9,516)	$ (288)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(2,960)	(2,353)
Net (loss) gain, net of tax expense of $(695) and $ 1,160, respectively	(2,085)	4,946
Amounts reclassified from accumulated other comprehensive loss to net loss, net of tax expense of $7 and $105, respectively	20	446
Defined benefit pension plans, net of tax	(2,065)	5,392
Other comprehensive (loss) income	(5,025)	3,039
Comprehensive (loss) income	$ (14,541)	$ 2,751

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Loss) (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined benefit pension plans, gain (loss), tax	$ (695)	$ 1,160
Defined benefit pension plans, reclassification, gain (loss), tax	$ 7	$ 105

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020	47,153,000
Balance at Dec. 31, 2020	$ 444	$ 232,357	$ (132,386)	$ (13,066)	$ (10,668)	$ 76,681
Retirement of treasury stock (in shares)	(7,746,000)
Retirement of treasury stock	$ 0	(10,668)	0	0	10,668	$ 0
Stock option exercises (in shares)	580,000					579,968
Stock option exercises	$ 8	2,869	0	0	0	$ 2,877
Employee stock purchase plan (in shares)	96,000					100,000
Employee stock purchase plan	$ 0	437	0	0	0	$ 437
Vesting of restricted stock units (in shares)	1,571,000
Vesting of restricted stock units	$ 0	0	0	0	0	0
Shares withheld for taxes (in shares)	(511,000)
Shares withheld for taxes	$ 0	(3,514)	0	0	0	(3,514)
Stock-based compensation expense	0	4,169	0	0	0	4,169
Net loss	0	0	(288)	0	0	(288)
Other comprehensive income	$ 0	0	0	3,039	0	3,039
Balance (in shares) at Dec. 31, 2021	41,143,000
Balance at Dec. 31, 2021	$ 452	225,650	(132,674)	(10,027)	0	$ 83,401
Stock option exercises (in shares)	40,000					40,267
Stock option exercises	$ 2	106	0	0	0	$ 108
Employee stock purchase plan (in shares)	176,000					200,000
Employee stock purchase plan	$ 0	469	0	0	0	$ 469
Vesting of restricted stock units (in shares)	1,135,000
Vesting of restricted stock units	$ 0	0	0	0	0	0
Shares withheld for taxes (in shares)	(412,000)
Shares withheld for taxes	$ 0	(1,628)	0	0	0	(1,628)
Stock-based compensation expense	0	4,411	0	0	0	4,411
Net loss	0	0	(9,516)	0	0	(9,516)
Other comprehensive income	$ 0	0	0	(5,025)	0	(5,025)
Balance (in shares) at Dec. 31, 2022	42,082,000
Balance at Dec. 31, 2022	$ 454	$ 229,008	$ (142,190)	$ (15,052)	$ 0	$ 72,220

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (9,516)	$ (288)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	1,453	1,781
Amortization of intangible assets	6,122	5,840
Amortization of deferred financing costs	280	280
Stock-based compensation expense	4,411	4,169
Deferred income taxes and other	(414)	(330)
Convertible Preferred Stock received in Biostage Settlement - Note 15	(3,900)	0
Changes in operating assets and liabilities:
Accounts receivable	4,780	(4,294)
Inventories	252	(5,861)
Other assets	474	(439)
Accounts payable and accrued expenses	(1,399)	2,454
Deferred revenue	(851)	505
Other liabilities	(540)	(2,555)
Net cash provided by operating activities	1,152	1,262
Cash flows from investing activities:
Additions to property, plant and equipment	(1,590)	(1,195)
Additions to intangible assets	0	(150)
Net cash used in investing activities	(1,590)	(1,345)
Cash flows from financing activities:
Borrowing on bank line of credit	7,800	4,250
Repayment on bank line of credit	(6,400)	(2,200)
Repayment of term debt	(3,186)	(2,000)
Debt issuance costs	0	(102)
Proceeds from exercise of stock options and employee stock purchase plan	577	3,314
Taxes paid related to net share settlement of equity awards	(1,628)	(3,514)
Net cash used in financing activities	(2,837)	(252)
Effect of exchange rate changes on cash	(38)	(161)
Decrease in cash and cash equivalents	(3,313)	(496)
Cash and cash equivalents at beginning of period	7,821	8,317
Cash and cash equivalents at end of period	4,508	7,821
Supplemental disclosures of cash flow information:
Cash paid for interest	2,314	1,577
Cash paid for income taxes, net of refunds	$ 534	$ 577

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Organization Harvard Bioscience, Inc., a Delaware corporation (the “Company”), is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe and China, the Company sells through a combination of direct and distribution channels to customers around the world. Risks and Uncertainties The global supply chain has experienced significant disruptions due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID- 19, 2023. Additionally, during 2022 The COVID- 19 2022, 19, 2022. 2022. If business interruptions resulting from the current macroeconomic conditions described above or from COVID- 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for inventory excess and obsolescence, income tax and reserves for bad debts as well as the defined benefit pension obligations. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill and the convertible preferred stock of Biostage held by the Company. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates. Cash and Cash Equivalents The Company considers all highly liquid instruments with original maturities of three December 31, 2022, Allowance for Doubtful Accounts The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on considering factors such as historical experience, credit quality, known troubled accounts, historical experience, factors that may Inventories The Company values its inventories at the lower of the actual cost to purchase ( first first Property, Plant and Equipment Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows: Machinery and equipment (years) 3 - 10 Computer equipment and software (years) 3 - 7 Furniture and fixtures (years) 5 - 10 Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Leases The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right to the Company to control the use of identified property, plant or equipment for period of time in exchange for consideration. Leases with an initial term of 12 not The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not 50% The Company’s policy is to account for Global Intangible Low-Taxed income as a period cost. Foreign Currency Translation The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of its foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive (loss) income (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in net (loss) income. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. Comprehensive Income (Loss) The Company reports all changes in equity during a period, resulting from net income (loss) and transactions from non-owner sources, in a financial statement in the period in which they are recognized. The Company discloses comprehensive income (loss), which encompasses net income (loss), foreign currency translation adjustments, gains and losses on derivatives, the underfunded status of its pension plans, and pension minimum additional liability adjustments, net of tax, in the consolidated statements of comprehensive income (loss). Revenue Recognition Nature of contracts and customers The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions. The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, including the United States National Institutes of Health and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer customers who incorporate its products into their products under their own brands. Performance obligations The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may not Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment, and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales on these items are therefore generally recognized at a point in time. The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may may, no may may not Service revenue consists of installation, training, data analysis, and surgeries performed on research animals. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised. These standard warranties are not one one For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment. Revenues expected to be recognized related to remaining performance obligations are generally expected to be recognized in one one Variable Consideration The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not not The Company’s payment terms are generally from zero sixty Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues. Deferred revenue The Company records deferred revenue when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Deferred revenue consists of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Deferred revenue is generally expected to be recognized within one The amounts included in deferred revenue from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not Advanced payments received from customers are recorded as a liability, and revenue is recognized when the Company’s performance obligations are completed. Performance obligations are completed when the product is shipped or delivered to the customer, or at the end of the exchange program if goods are not Disaggregation of revenue Refer to Note 12 16 Definite-lived Intangible Assets Definite-lived Intangible assets are comprised of existing technology, customer contracts and contractual relationships, and other definite-lived intangible assets. Identifiable intangible assets resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by the Company based on the fair value of assets received. Identifiable definite-lived intangible assets are being amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from four fifteen The Company amortizes definite-lived intangible assets over their estimated useful lives and evaluates definite-lived assets for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not not When the Company determines that the carrying value of the assets may not one not Goodwill Goodwill acquired in a business combination and determined to have an indefinite useful life is not For the purpose of its goodwill analysis, the Company has one reporting unit. The Company conducts its annual impairment analysis in the fourth not The Company evaluated its goodwill for impairment as of October 1, 2022 October 1, 2022, Impairment of Long-Lived Assets The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets in accordance with ASC 360, may not December 31, 2022, none Derivatives The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations and may not not Valuation of Investment in Preferred Stock On June 10, 2022, third 15 The Company recorded the Series E Preferred Stock at an initial estimated fair value of $3.9 million using an income approach which considered a discount rate and an estimated time until conversion into Biostage Inc. common stock. The Company has elected the provisions within ASC 321 Investment Securities December 31, 2022, no Fair Value of Financial Instruments Financial reporting standards define a fair value hierarchy that consists of three § Level 1 § Level 2 not § Level 3 The carrying values of the Company’s cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity (Level 2 Stock-based Compensation The Company accounts for stock-based payment awards in accordance with the provisions of ASC 718, 2021 “2021 2000 “2000 2021 Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company values stock-based payment awards, except restricted stock units at grant date using the Black-Scholes option-pricing model. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model or Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables. These variables include, but are not The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant and are recorded as compensation expense on a straight-line basis over the applicable service period, which ranges from one four Recent Accounting Pronouncements Accounting Pronouncements Adopted In November 2021, 2021 10 , Government Assistance (Topic 832 2021 10 2021 10 January 1, 2022 2021 10 17. Accounting Pronouncements to be Adopted In January 2017, 2017 04, Intangibles Goodwill and Other (Topic 350 2017 04 2 2017 04 December 15, 2022. 2017 04 not In September 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 Instruments (ASU 2016 13 may 2016 13 2016 13 December 15, 2022, 2016 13 not

Note 3 - Accumulated Other Comp

Note 3 - Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	3. Accumulated Other Comprehensive Loss Changes in the components of accumulated other comprehensive loss, net of tax, for the years ended December 31, 2022 2021, Foreign currency translation Defined benefit (in thousands) adjustments pension plans Total Balance at December 31, 2020 $ (11,473 ) $ (1,593 ) $ (13,066 ) Other comprehensive income (loss) before reclassifications (2,353 ) 4,946 2,593 Amounts reclassified from AOCI - 446 446 Net other comprehensive (loss) income (2,353 ) 5,392 3,039 Balance at December 31, 2021 (13,826 ) 3,799 (10,027 ) Other comprehensive income (loss) before reclassifications (2,960 ) (2,085 ) (5,046 ) Amounts reclassified from AOCI - 20 20 Net other comprehensive (loss) income (2,960 ) (2,065 ) (5,025 ) Balance at December 31, 2022 $ (16,786 ) $ 1,734 $ (15,052 )

Note 4 - Goodwill and Intangibl

Note 4 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4. Goodwill and Intangible Assets The change in the carrying amount of goodwill is as follows: December 31, 2022 2021 (in thousands) Carrying amount at beginning of period $ 57,689 $ 58,590 Effect of change in currency translation (1,429 ) (901 ) Carrying amount at end of period $ 56,260 $ 57,689 Identifiable intangible assets at December 31, 2022 2021 December 31, 2022 December 31, 2021 (in thousands) Average Accumulated Accumulated Amortizable intangible assets: Life* Gross Amortization Net Gross Amortization Net Distribution agreements/customer relationships 7.2 $ 16,124 $ (8,727 ) $ 7,397 $ 17,689 $ (8,675 ) $ 9,014 Existing technology 3.2 37,549 (26,482 ) 11,067 38,707 (23,962 ) 14,745 Trade names and patents 3.7 7,523 (5,197 ) 2,326 8,496 (5,108 ) 3,388 Total amortizable intangible assets $ 61,196 $ (40,406 ) $ 20,790 $ 64,892 $ (37,745 ) $ 27,147 Indefinite-lived intangible assets: 224 238 Total intangible assets $ 21,014 $ 27,385 * Weighted average life in years as of December 31, 2022 During the year ended December 31, 2022, Intangible asset amortization expense was $6.1 million and $5.8 million of the years ended December 31, 2022 2021, five (in thousands) 2023 $ 5,546 2024 5,248 2025 4,020 2026 2,359 2027 1,262 Thereafter 2,355 Total $ 20,790

Note 5 - Balance Sheet Informat

Note 5 - Balance Sheet Information	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	5. Balance Sheet Information The following tables provide details of selected balance sheet items as of the periods indicated: Inventories: December 31, (in thousands) 2022 2021 Finished goods $ 5,223 $ 5,646 Work in process 3,776 3,410 Raw materials 17,440 18,531 Total $ 26,439 $ 27,587 Property, Plant and Equipment: December 31, (in thousands) 2022 2021 Machinery and equipment $ 7,500 $ 7,698 Computer equipment and software 6,781 6,269 Leasehold improvements 2,507 2,560 Furniture and fixtures 1,386 1,296 Automobiles 38 41 18,212 17,864 Less: accumulated depreciation (14,846 ) (14,449 ) Property, plant and equipment, net $ 3,366 $ 3,415 During the year ended December 31, 2022, Other Current Liabilities: December 31, (in thousands) 2022 2021 Compensation $ 3,476 $ 6,048 Professional fees 392 480 Warranty costs 268 240 Customer advances 2,368 2,265 Accrued income taxes - 224 Other 982 1,505 Total $ 7,486 $ 10,762

Note 6 - Restructuring and Othe

Note 6 - Restructuring and Other Exit Costs	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	6. Restructuring and Other Exit Costs On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420 Exit or Disposal Cost Obligations The Company initiated a restructuring plan in 2019 December 31, 2021, 2021. During the year ended December 31, 2022, The following table summarizes the restructuring activity for the years ended December 31, 2022 2021: Cost of (in thousands) Revenues Severance Other Total Balance at December 31, 2020 $ - $ 270 $ 18 $ 288 Restructuring and other exit costs - 1,174 101 1,275 Non-cash charges - - (46 ) (46 ) Cash payments - (1,444 ) (73 ) (1,517 ) Balance at December 31, 2021 $ - $ - $ - $ - Restructuring and other exit costs 1,471 877 46 2,394 Non-cash charges (1,471 ) - - (1,471 ) Cash payments - (241 ) (46 ) (287 ) Balance at December 31, 2022 $ - $ 636 $ - $ 636 Substantially all of the severance and other costs detailed above have been included as a component of general and administrative expenses.

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	7. Related Party Transactions In connection with the 2014 2021. December 31, 2024. December 31, 2022 2021.

Note 8 - Employee Benefit Plans

Note 8 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Retirement Benefits [Text Block]	8. Employee Benefit Plans Employee Retirement Savings Plans The Company sponsors various qualified employee retirement savings plans and makes discretionary contributions to match a certain portion of employee contributions. For the years ended December 31, 2022 2021, Employee Pension Plans The Company’s subsidiary in the United Kingdom, Biochrom Limited maintains contributory, defined benefit pension plans for its employees. In 2014, 715 20 715 20 not The components of the Company’s net period benefit (credit) expense were as follows: Year Ended December 31, (in thousands) 2022 2021 Interest cost $ 371 $ 358 Expected return on plan assets (818 ) (675 ) Net amortization loss 27 551 Recognition of net loss due to settlements - 115 Net periodic benefit (credit) cost $ (420 ) $ 349 The following provides a reconciliation of the changes in the plans’ benefit obligations and fair value of assets for the years ended December 31, 2022 2021, December 31, 2022 2021: December 31, (in thousands) 2022 2021 Change in benefit obligation: Balance at beginning of year $ 22,562 $ 25,519 Interest cost 371 358 Actuarial (gain) loss (6,912 ) (2,440 ) Settlements due to transfers paid - (198 ) Benefits paid (592 ) (498 ) Currency translation adjustment (2,166 ) (179 ) Balance at end of year $ 13,263 $ 22,562 Changes in the actuarial gain disclosed above are primarily the result of changes in the discount rate and inflation assumptions due to underlying market conditions. December 31, (in thousands) 2022 2021 Change in fair value of plan assets: Balance at beginning of year $ 27,252 $ 23,926 Actual return on plan assets (9,098 ) 3,354 Employer contributions 619 1,042 Settlement due to transfers paid - (270 ) Benefits paid (592 ) (498 ) Currency translation adjustment (2,605 ) (302 ) Balance at end of year $ 15,576 $ 27,252 December 31, (in thousands) 2022 2021 Benefit obligation $ 13,263 $ 22,562 Fair value of plan assets 15,576 27,252 Net funded status $ 2,313 $ 4,690 The amounts recognized in the consolidated balance sheets consist of: December 31, (in thousands) 2022 2021 Other long-term assets $ 2,313 $ 4,690 Deferred income tax liabilities (579 ) (891 ) Recognized in accumulated other comprehensive loss $ 1,734 $ 3,799 The weighted average assumptions used in determining the net pension cost for these plans follows: Year Ended December 31, 2022 2021 Discount rate 5.0 % 1.8 % Expected return on assets 5.0 % 2.8 % The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations. The Company’s mix of pension plan investments among asset classes also affects the long-term expected rate of return on plan assets. As of December 31, 2022, 8 The fair value and asset allocations of the Company’s pension benefits as of December 31, 2022 2021 December 31, (in thousands) 2022 2021 Asset category: Equity securities $ 3,507 23 % $ 14,295 52 % Debt securities 11,714 75 % 4,720 17 % Liability driven investment funds - - 5,722 21 % Cash and cash equivalents 185 1 % 1,907 7 % Other 170 1 % 608 2 % Total $ 15,576 100 % $ 27,252 100 % Financial reporting standards define a fair value hierarchy that consists of three December 31, 2022 2021, December 31, (in thousands) 2022 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) $ 185 $ 1,907 Significant Other Observable Inputs (Level 2) 15,391 25,345 Significant Other Unobservable Inputs (Level 3) - - Total $ 15,576 $ 27,252 Level 1 2 not The Company expects to contribute approximately $0.6 million to its pension plans during 2023. 2023, 2024, 2025, 2026 2027. five 2028 2032 December 31, 2022.

Note 9 - Leases

Note 9 - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases The Company has noncancelable operating leases for office space, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030. The components of lease expense for the years ended December 31, 2022 2021 Year Ended December 31, (in thousands) 2022 2021 Operating lease cost $ 1,971 $ 2,041 Short-term lease cost 233 196 Sublease income (102 ) (102 ) Total lease cost $ 2,102 $ 2,135 Supplemental cash flow information related to the Company’s operating leases was as follows: Year Ended December 31, (in thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: $ 2,347 $ 2,365 Right-of-use assets obtained in exchange for lease obligations: $ 295 $ 524 Supplemental balance sheet information related to the Company’s operating leases was as follows: December 31, (in thousands) 2022 2021 Operating lease right-of-use assets $ 5,816 $ 6,897 Current portion, operating lease liabilities $ 2,135 $ 2,142 Operating lease liabilities, long-term 5,282 6,488 Total operating lease liabilities $ 7,417 $ 8,630 Weighted average remaining lease term (years) 6.2 6.7 Weighted average discount rate 9.4 % 9.3 % Future minimum lease payments for operating leases, with initial terms in excess of one December 31, 2022, (in thousands) 2023 $ 2,135 2024 1,794 2025 1,064 2026 1,022 2027 1,004 Thereafter 2,995 Total lease payments 10,014 Less imputed interest (2,597 ) Total operating lease liabilities $ 7,417

Note 10 - Capital Stock and Sto

Note 10 - Capital Stock and Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Shareholders' Equity and Share-Based Payments [Text Block]	10. Capital Stock and Stock-Based Compensation Retirement of Treasury Stock In May 2021, Preferred Stock The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may December 31, 2022 2021, no Employee Stock Purchase Plan ( ESPP ) Under the ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six six June 30 December 31. December 31, 2022 2021, December 31, 2022, Equity Incentive Plans During 2021, 2021 2021 December 31, 2022, 2021 Performance Restricted Stock Units The Company grants awards of Performance Market Condition RSUs (the “PRSUs”) to certain members of the Company’s management team. The vesting of the PRSUs is linked to the achievement of a relative total shareholder return of the Company’s common stock measured from the earlier of (i) the measurement period as set out in the award agreement or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology or Russell 2000 20 For PRSUs granted during the year ended December 31, 2020, December 31, 2021. December 31, 2022 Stock-Based Payment Awards The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, no Stock option and restricted stock unit activity under the Company’s Incentive Plans for the years ended December 31, 2022 2021 Weighted Stock Average Time-Based Performance- Options Exercise RSUs Grant Date Based RSUs Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2020 2,637,339 $ 3.51 1,560,461 $ 2.44 813,031 $ 2.12 Granted - - 820,831 4.74 293,509 4.61 Exercised (579,968 ) 3.77 - - - - Vested (RSUs) - - (1,167,473 ) 2.88 (403,422 ) 2.11 Cancelled/Forfeited (652,555 ) 4.24 (72,655 ) 3.67 (6,179 ) 2.98 Performance Factor Adjustment - - - - 163,216 2.98 Balance at December 31, 2021 1,404,816 $ 3.10 1,141,164 $ 3.57 860,155 $ 3.13 Granted - - 918,870 4.64 320,272 5.08 Exercised (40,267 ) 2.64 - - - - Vested (RSUs) - - (733,611 ) 4.08 (401,308 ) 2.11 Cancelled/Forfeited (125,773 ) 2.77 (232,622 ) 4.44 (132,884 ) 4.21 Balance at December 31, 2022 1,238,776 $ 3.15 1,093,801 $ 3.94 646,235 $ 4.51 Earnings per share Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following: Year Ended December 31, (in thousands) 2022 2021 Weighted average shares outstanding - basic 41,413 40,343 Dilutive effect of equity awards - - Weighted average shares outstanding - diluted 41,413 40,343 Shares excluded from diluted loss per share due to their anti-dilutive effect 3,661 4,274 The following table summarizes outstanding and exercisable options as of December 31, 2022 ( Options Outstanding Options Exercisable Weighted Weighted Average Weighted Average Weighted Range of Remaining Average Aggregate Remaining Average Aggregate Exercise Number Contractual Life Exercise Intrinsic Shares Contractual Life Exercise Intrinsic Price Outstanding in Years Price Value Exercisable in Years Price Value $ 1.78 - 2.62 135,342 6.3 $ 1.89 $ 119 102,381 6.2 $ 1.91 $ 88 2.63 - 2.78 505,423 4.4 2.63 71 357,192 4.4 2.63 50 2.79 - 3.24 135,077 6.6 2.93 - 135,077 6.6 2.93 - 3.25 - 3.72 206,808 4.2 3.38 - 206,808 4.2 3.38 - 3.73 - 5.51 256,126 3.2 4.76 - 238,222 3.0 4.83 - $ 1.78 - 5.51 1,238,776 4.6 $ 3.15 $ 190 1,039,680 4.5 $ 3.25 $ 138 The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $2.77 as of December 31, 2022, December 31, 2022 2021, As of December 31, 2022, not December 31, 2022 2021, not Valuation and Expense Information under Stock-Based-Payment Accounting Stock-based compensation expenses related to stock options, restricted stock units, Market Condition RSU’s and the ESPP for the years ended December 31, 2022 2021 Year Ended December 31, (in thousands) 2022 2021 Cost of revenues $ 121 $ 118 Sales and marketing expenses 557 507 General and administrative expenses 3,487 3,416 Research and development expenses 246 128 Total stock-based compensation expenses $ 4,411 $ 4,169 The weighted average estimated fair value per share of the Market Condition RSUs granted during the years ended December 31, 2022 2021 2022 2021 Volatility 62.6 % 65.1 % Risk-free interest rate 2.1 % 0.3 % Correlation coefficient 41.5 % 35.7 % Dividend yield - % - % The Company used historical volatility to calculate the expected volatility. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options. The expected holding period of stock options represents the period of time options are expected to be outstanding and were based on historical experience. The vesting period ranges from one four ten

Note 11 - Long-term Debt

Note 11 - Long-term Debt	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	11. Long-Term Debt As of December 31, 2022 December 31, 2021, December 31, December 31, (in thousands) 2022 2021 Long-term debt: Term loan $ 34,814 $ 38,000 Revolving line 12,850 11,450 Less: unamortized deferred financing costs (840 ) (1,120 ) Total debt 46,824 48,330 Less: current installments (4,091 ) (3,515 ) Current unamortized deferred financing costs 280 280 Long-term debt $ 43,013 $ 45,095 The aggregate amounts of debt maturing during the next five (in thousands) 2023 $ 4,091 2024 4,000 2025 39,573 $ 47,664 On December 22, 2020, none December 22, 2025. December 31, 2022 April 2022 November 2022 As part of the November 2022 November 2022 three six no The effective interest rate on the Company’s borrowings for the years ended December 31, 2022 2021, December 31, 2022 Commencing on March 31, 2021, three eight ninety may December 31, 2022, March 31, 2023. The Credit Agreement, as amended, includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement, as amended, also includes customary events of default. The April 28, 2022 15 April 28, 2022 The November 8, 2022 November 2022 The Company was in compliance with the covenants of the Credit Agreement, as amended, as of December 31, 2022. The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations by the use of cash flow sensitivity analysis which estimates the expected impact of changes in interest rates on the Company’s future cash flows.

Note 12 - Revenues

Note 12 - Revenues	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	12. Revenues The following table represents a disaggregation of revenue from contracts with customers for the years ended December 31, 2022 2021: Year Ended December 31, (in thousands) 2022 2021 Instruments, equipment, software and accessories $ 108,165 $ 114,115 Service, maintenance and warranty contracts 5,170 4,789 Total revenues $ 113,335 $ 118,904 Deferred revenue The following tables provide details of deferred revenue as of the periods indicated: December 31, (in thousands) 2022 2021 Service contracts $ 1,530 $ 1,976 Customer advances 1,840 2,290 Total deferred revenue $ 3,370 $ 4,266 During the years ended December 31, 2022 2021, December 31, 2021 2020, Allowance for Doubtful Accounts Allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. A rollforward of allowance for doubtful accounts is as follows: December 31, (in thousands) 2022 2021 Balance, beginning of period $ 136 $ 227 Bad debt expense (credit) 62 (4 ) Charge-offs and other (7 ) (87 ) Balance, end of period $ 191 $ 136 Concentrations No 10% December 31, 2022, 2021, 10% December 31, 2022 2021. Warranties Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows: December 31, (in thousands) 2022 2021 Balance, beginning of period $ 240 $ 186 Expense 408 319 (Charges)/Credits (380 ) (265 ) Balance, end of period $ 268 $ 240

Note 13 - Income Tax

Note 13 - Income Tax	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Tax Income tax expense for years ended December 31, 2022 2021 Year Ended December 31, (in thousands) 2022 2021 Current income tax expense: Federal and state $ 641 $ 363 Foreign 194 156 835 519 Deferred income tax (benefit) expense: Federal and state (468 ) 22 Foreign (30 ) (393 ) (498 ) (371 ) Total income tax expense $ 337 $ 148 The effective tax rate for the year ended December 31, 2022 2021. Income tax expense for the years ended December 31, 2022 2021 21% Year Ended December 31, (in thousands) 2022 2021 Provision for income taxes at federal statutory rates $ (1,927 ) $ (29 ) Increase (decrease) in income taxes resulting from: Permanent differences, net 375 (362 ) Non-deductible executive compensation 346 412 Global Intangible Low-Taxed Income (GILTI) 552 - Foreign tax rate differential (103 ) (217 ) State income taxes, net of federal income tax benefit (295 ) (16 ) Non-deductible stock compensation expense 69 280 Tax credits 492 455 Net operating loss true-ups and expirations 431 195 Change in reserve for uncertain tax position 688 (118 ) Impact of change to prior year tax accruals (232 ) 269 Change in valuation allowance allocated to income tax (102 ) (961 ) Other 43 240 Total income tax expense $ 337 $ 148 Income tax expense is based on the following pre-tax income (loss) from operations: Year Ended December 31, (in thousands) 2022 2021 Domestic $ (9,099 ) $ 2,364 Foreign (80 ) (2,504 ) Total $ (9,179 ) $ (140 ) The tax effects of temporary differences that give rise to significant components of the deferred tax assets and deferred tax liabilities at December 31, 2022 2021 Year Ended December 31, (in thousands) 2022 2021 Deferred income tax assets: Inventory $ 1,696 $ 1,280 Operating loss and credit carryforwards 14,883 18,046 Accrued expenses 621 835 Deferred interest expense 881 1,191 Stock compensation 675 580 Lease liability 1,538 1,693 Research and development 2,000 - Other assets 726 386 Total gross deferred assets 23,020 24,011 Less: valuation allowance (14,506 ) (14,700 ) Deferred tax assets $ 8,514 $ 9,311 Deferred income tax liabilities: Indefinite-lived intangible assets $ 1,914 $ 1,882 Definite-lived intangible assets 4,875 6,277 Right-of-use asset 1,148 1,277 Other liabilities 834 1,228 Total deferred tax liabilities 8,771 10,664 Deferred income tax liability, net $ (257 ) $ (1,353 ) Deferred income tax assets and liabilities by classification on the consolidated balance sheets were as follows: Year Ended December 31, (in thousands) 2022 2021 Deferred tax assets (included in other long-term assets) $ 333 $ 205 Deferred income tax liabilities (590 ) (1,558 ) Deferred income tax liability, net $ (257 ) $ (1,353 ) As of December 31, 2022 2021, December 31, 2022 December 31, 2021 2022 2021 December 31, 2021 At December 31, 2022, 2029 2038. 2023 2042. may 2023. 2023. 2036. may one 382 383. As of December 31, 2022 December 31, 2021, December 31, 2022, At December 31, 2022 2021 (in thousands) Balance at December 31, 2020 $ 1,673 Decreases based on tax positions of prior years (208 ) Additions based on tax positions of current years 176 Decreases based on expiration of statutes of limitation (42 ) Settlements and other (267 ) Balance at December 31, 2021 1,332 Additions based on tax positions of prior years 534 Decreases based on tax positions of prior years (34 ) Additions based on tax positions of current years 237 Decreases based on expiration of statutes of limitation (86 ) Balance at December 31, 2022 $ 1,983 The Company does not 12 not December 31, 2022 2021, The Company or one no 2018. 2003 no On August 16, 2022, 2022 15% 1% December 31, 2022. not

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingent Liabilities On April 27, 2022, 15 The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not not not one In addition, the Company has entered into indemnification agreements with its directors. It is not not December 31, 2022.

Note 15 - Litigation Settlement

Note 15 - Litigation Settlement	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	15. Litigation Settlement On April 14, 2017, 2013, third one two third 2012 2013. On April 27, 2022, not During the three March 31, 2022, December 31, 2021, During the three June 30, 2022 September 30, 2022, June 10, 2022, The Series E Preferred Stock ranks senior to all classes of common stock of Biostage and all classes of preferred stock of Biostage (unless the Company consents to Biostage’s issuance of other preferred stock that is senior to or pari passu with the Series E Preferred Stock) and accrues dividends at a rate of 8% per annum that are payable in additional shares of Series E Preferred Stock. Each share of Series E Preferred Stock is convertible at any time at the option of the Company into such number of shares of Biostage common stock determined by dividing (a) the $1,000 face value of the Series E Preferred Stock plus all accrued and unpaid dividends thereon by (b) the average of the volume weighted average trading prices of Biostage’s common stock, which is currently quoted on the OTCQB Marketplace, for the 60 first first The book value of the Series E Preferred Stock, inclusive of accrued dividends, is $4.1 million and is included in the December 31, 2022 321 Investment Securities December 31, 2022, no no

Note 16 - Segment and Related I

Note 16 - Segment and Related Information	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Segment and Related Information Operating segments are determined by products and services provided by each segment, internal organization structure, the manner in which operations are managed, criteria used by the Chief Operating Decision Maker, or CODM, to assess the segment performance, as well as resource allocation and the availability of discrete financial information. The Company has one The following tables summarize additional selected financial information of the Company’s operations by geographic location. Revenues by geographic destination are as follows: Year Ended December 31, (in thousands) 2022 2021 United States $ 49,912 $ 49,831 Europe 30,687 35,767 Greater China 16,393 13,496 Rest of the world 16,343 19,810 Total revenues $ 113,335 $ 118,904 Long-lived assets by geographic area include operating lease right-of-use assets, property, plant and equipment, and amortizable intangible assets, are as follows: December 31, (in thousands) 2022 2021 United States $ 26,051 $ 31,512 Germany 2,432 3,501 Rest of the world 1,489 2,446 Total long-lived assets $ 29,972 $ 37,459 Net assets by geographic area are as follows: December 31, (in thousands) 2022 2021 United States $ 34,408 $ 38,641 Germany 14,761 15,501 United Kingdom 10,116 13,999 Rest of the world 12,935 15,260 Total net assets $ 72,220 $ 83,401

Note 17 - Government Assistance

Note 17 - Government Assistance	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Government Assistance [Text Block]	17. Government Assistance For the year ended December 31, 2022, 19 19

Note 18 - Subsequent Event - De

Note 18 - Subsequent Event - Derivatives	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	18. Subsequent Event - Derivatives On February 28, 2023, December 22, 2025. not 11 may no

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for inventory excess and obsolescence, income tax and reserves for bad debts as well as the defined benefit pension obligations. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill and the convertible preferred stock of Biostage held by the Company. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid instruments with original maturities of three December 31, 2022,
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on considering factors such as historical experience, credit quality, known troubled accounts, historical experience, factors that may
Inventory, Policy [Policy Text Block]	Inventories The Company values its inventories at the lower of the actual cost to purchase ( first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows: Machinery and equipment (years) 3 - 10 Computer equipment and software (years) 3 - 7 Furniture and fixtures (years) 5 - 10 Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.
Lessee, Leases [Policy Text Block]	Leases The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right to the Company to control the use of identified property, plant or equipment for period of time in exchange for consideration. Leases with an initial term of 12 not The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not 50% The Company’s policy is to account for Global Intangible Low-Taxed income as a period cost.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of its foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive (loss) income (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in net (loss) income.
Earnings Per Share, Policy [Policy Text Block]	Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.
Comprehensive Income (Loss) [Policy Text Block]	Comprehensive Income (Loss) The Company reports all changes in equity during a period, resulting from net income (loss) and transactions from non-owner sources, in a financial statement in the period in which they are recognized. The Company discloses comprehensive income (loss), which encompasses net income (loss), foreign currency translation adjustments, gains and losses on derivatives, the underfunded status of its pension plans, and pension minimum additional liability adjustments, net of tax, in the consolidated statements of comprehensive income (loss).
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Nature of contracts and customers The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions. The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, including the United States National Institutes of Health and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer customers who incorporate its products into their products under their own brands. Performance obligations The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may not Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment, and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales on these items are therefore generally recognized at a point in time. The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may may, no may may not Service revenue consists of installation, training, data analysis, and surgeries performed on research animals. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised. These standard warranties are not one one For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment. Revenues expected to be recognized related to remaining performance obligations are generally expected to be recognized in one one Variable Consideration The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not not The Company’s payment terms are generally from zero sixty Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues. Deferred revenue The Company records deferred revenue when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Deferred revenue consists of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Deferred revenue is generally expected to be recognized within one The amounts included in deferred revenue from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not Advanced payments received from customers are recorded as a liability, and revenue is recognized when the Company’s performance obligations are completed. Performance obligations are completed when the product is shipped or delivered to the customer, or at the end of the exchange program if goods are not Disaggregation of revenue Refer to Note 12 16
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Definite-lived Intangible Assets Definite-lived Intangible assets are comprised of existing technology, customer contracts and contractual relationships, and other definite-lived intangible assets. Identifiable intangible assets resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by the Company based on the fair value of assets received. Identifiable definite-lived intangible assets are being amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from four fifteen The Company amortizes definite-lived intangible assets over their estimated useful lives and evaluates definite-lived assets for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not not When the Company determines that the carrying value of the assets may not one not
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill acquired in a business combination and determined to have an indefinite useful life is not For the purpose of its goodwill analysis, the Company has one reporting unit. The Company conducts its annual impairment analysis in the fourth not The Company evaluated its goodwill for impairment as of October 1, 2022 October 1, 2022,
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets in accordance with ASC 360, may not December 31, 2022, none
Derivatives, Policy [Policy Text Block]	Derivatives The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations and may not not
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	Valuation of Investment in Preferred Stock On June 10, 2022, third 15 The Company recorded the Series E Preferred Stock at an initial estimated fair value of $3.9 million using an income approach which considered a discount rate and an estimated time until conversion into Biostage Inc. common stock. The Company has elected the provisions within ASC 321 Investment Securities December 31, 2022, no
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Financial reporting standards define a fair value hierarchy that consists of three § Level 1 § Level 2 not § Level 3 The carrying values of the Company’s cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity (Level 2
Share-Based Payment Arrangement [Policy Text Block]	Stock-based Compensation The Company accounts for stock-based payment awards in accordance with the provisions of ASC 718, 2021 “2021 2000 “2000 2021 Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company values stock-based payment awards, except restricted stock units at grant date using the Black-Scholes option-pricing model. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model or Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables. These variables include, but are not The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant and are recorded as compensation expense on a straight-line basis over the applicable service period, which ranges from one four
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Accounting Pronouncements Adopted In November 2021, 2021 10 , Government Assistance (Topic 832 2021 10 2021 10 January 1, 2022 2021 10 17. Accounting Pronouncements to be Adopted In January 2017, 2017 04, Intangibles Goodwill and Other (Topic 350 2017 04 2 2017 04 December 15, 2022. 2017 04 not In September 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 Instruments (ASU 2016 13 may 2016 13 2016 13 December 15, 2022, 2016 13 not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Property, Plant and Equipment, Useful Lives [Table Text Block]	Machinery and equipment (years) 3 - 10 Computer equipment and software (years) 3 - 7 Furniture and fixtures (years) 5 - 10

Note 3 - Accumulated Other Co_2

Note 3 - Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Foreign currency translation Defined benefit (in thousands) adjustments pension plans Total Balance at December 31, 2020 $ (11,473 ) $ (1,593 ) $ (13,066 ) Other comprehensive income (loss) before reclassifications (2,353 ) 4,946 2,593 Amounts reclassified from AOCI - 446 446 Net other comprehensive (loss) income (2,353 ) 5,392 3,039 Balance at December 31, 2021 (13,826 ) 3,799 (10,027 ) Other comprehensive income (loss) before reclassifications (2,960 ) (2,085 ) (5,046 ) Amounts reclassified from AOCI - 20 20 Net other comprehensive (loss) income (2,960 ) (2,065 ) (5,025 ) Balance at December 31, 2022 $ (16,786 ) $ 1,734 $ (15,052 )

Note 4 - Goodwill and Intangi_2

Note 4 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Goodwill [Table Text Block]	December 31, 2022 2021 (in thousands) Carrying amount at beginning of period $ 57,689 $ 58,590 Effect of change in currency translation (1,429 ) (901 ) Carrying amount at end of period $ 56,260 $ 57,689
Schedule of Intangible Assets and Goodwill [Table Text Block]	December 31, 2022 December 31, 2021 (in thousands) Average Accumulated Accumulated Amortizable intangible assets: Life* Gross Amortization Net Gross Amortization Net Distribution agreements/customer relationships 7.2 $ 16,124 $ (8,727 ) $ 7,397 $ 17,689 $ (8,675 ) $ 9,014 Existing technology 3.2 37,549 (26,482 ) 11,067 38,707 (23,962 ) 14,745 Trade names and patents 3.7 7,523 (5,197 ) 2,326 8,496 (5,108 ) 3,388 Total amortizable intangible assets $ 61,196 $ (40,406 ) $ 20,790 $ 64,892 $ (37,745 ) $ 27,147 Indefinite-lived intangible assets: 224 238 Total intangible assets $ 21,014 $ 27,385
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(in thousands) 2023 $ 5,546 2024 5,248 2025 4,020 2026 2,359 2027 1,262 Thereafter 2,355 Total $ 20,790

Note 5 - Balance Sheet Inform_2

Note 5 - Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Inventories: December 31, (in thousands) 2022 2021 Finished goods $ 5,223 $ 5,646 Work in process 3,776 3,410 Raw materials 17,440 18,531 Total $ 26,439 $ 27,587
Property, Plant and Equipment [Table Text Block]	Property, Plant and Equipment: December 31, (in thousands) 2022 2021 Machinery and equipment $ 7,500 $ 7,698 Computer equipment and software 6,781 6,269 Leasehold improvements 2,507 2,560 Furniture and fixtures 1,386 1,296 Automobiles 38 41 18,212 17,864 Less: accumulated depreciation (14,846 ) (14,449 ) Property, plant and equipment, net $ 3,366 $ 3,415
Other Current Liabilities [Table Text Block]	Other Current Liabilities: December 31, (in thousands) 2022 2021 Compensation $ 3,476 $ 6,048 Professional fees 392 480 Warranty costs 268 240 Customer advances 2,368 2,265 Accrued income taxes - 224 Other 982 1,505 Total $ 7,486 $ 10,762

Note 6 - Restructuring and Ot_2

Note 6 - Restructuring and Other Exit Costs (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Restructuring and Related Costs [Table Text Block]	Cost of (in thousands) Revenues Severance Other Total Balance at December 31, 2020 $ - $ 270 $ 18 $ 288 Restructuring and other exit costs - 1,174 101 1,275 Non-cash charges - - (46 ) (46 ) Cash payments - (1,444 ) (73 ) (1,517 ) Balance at December 31, 2021 $ - $ - $ - $ - Restructuring and other exit costs 1,471 877 46 2,394 Non-cash charges (1,471 ) - - (1,471 ) Cash payments - (241 ) (46 ) (287 ) Balance at December 31, 2022 $ - $ 636 $ - $ 636

Note 8 - Employee Benefit Pla_2

Note 8 - Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Costs of Retirement Plans [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Interest cost $ 371 $ 358 Expected return on plan assets (818 ) (675 ) Net amortization loss 27 551 Recognition of net loss due to settlements - 115 Net periodic benefit (credit) cost $ (420 ) $ 349
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	December 31, (in thousands) 2022 2021 Change in benefit obligation: Balance at beginning of year $ 22,562 $ 25,519 Interest cost 371 358 Actuarial (gain) loss (6,912 ) (2,440 ) Settlements due to transfers paid - (198 ) Benefits paid (592 ) (498 ) Currency translation adjustment (2,166 ) (179 ) Balance at end of year $ 13,263 $ 22,562
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]	December 31, (in thousands) 2022 2021 Change in fair value of plan assets: Balance at beginning of year $ 27,252 $ 23,926 Actual return on plan assets (9,098 ) 3,354 Employer contributions 619 1,042 Settlement due to transfers paid - (270 ) Benefits paid (592 ) (498 ) Currency translation adjustment (2,605 ) (302 ) Balance at end of year $ 15,576 $ 27,252
Schedule of Net Funded Status [Table Text Block]	December 31, (in thousands) 2022 2021 Benefit obligation $ 13,263 $ 22,562 Fair value of plan assets 15,576 27,252 Net funded status $ 2,313 $ 4,690
Schedule of Amounts Recognized in Balance Sheet [Table Text Block]	December 31, (in thousands) 2022 2021 Other long-term assets $ 2,313 $ 4,690 Deferred income tax liabilities (579 ) (891 ) Recognized in accumulated other comprehensive loss $ 1,734 $ 3,799
Defined Benefit Plan, Assumptions [Table Text Block]	Year Ended December 31, 2022 2021 Discount rate 5.0 % 1.8 % Expected return on assets 5.0 % 2.8 %
Schedule of Allocation of Plan Assets [Table Text Block]	December 31, (in thousands) 2022 2021 Asset category: Equity securities $ 3,507 23 % $ 14,295 52 % Debt securities 11,714 75 % 4,720 17 % Liability driven investment funds - - 5,722 21 % Cash and cash equivalents 185 1 % 1,907 7 % Other 170 1 % 608 2 % Total $ 15,576 100 % $ 27,252 100 %
Defined Benefit Plan, Plan Assets, Category [Table Text Block]	December 31, (in thousands) 2022 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) $ 185 $ 1,907 Significant Other Observable Inputs (Level 2) 15,391 25,345 Significant Other Unobservable Inputs (Level 3) - - Total $ 15,576 $ 27,252

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Operating lease cost $ 1,971 $ 2,041 Short-term lease cost 233 196 Sublease income (102 ) (102 ) Total lease cost $ 2,102 $ 2,135
Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: $ 2,347 $ 2,365 Right-of-use assets obtained in exchange for lease obligations: $ 295 $ 524
Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]	December 31, (in thousands) 2022 2021 Operating lease right-of-use assets $ 5,816 $ 6,897 Current portion, operating lease liabilities $ 2,135 $ 2,142 Operating lease liabilities, long-term 5,282 6,488 Total operating lease liabilities $ 7,417 $ 8,630 Weighted average remaining lease term (years) 6.2 6.7 Weighted average discount rate 9.4 % 9.3 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(in thousands) 2023 $ 2,135 2024 1,794 2025 1,064 2026 1,022 2027 1,004 Thereafter 2,995 Total lease payments 10,014 Less imputed interest (2,597 ) Total operating lease liabilities $ 7,417

Note 10 - Capital Stock and S_2

Note 10 - Capital Stock and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]	Weighted Stock Average Time-Based Performance- Options Exercise RSUs Grant Date Based RSUs Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2020 2,637,339 $ 3.51 1,560,461 $ 2.44 813,031 $ 2.12 Granted - - 820,831 4.74 293,509 4.61 Exercised (579,968 ) 3.77 - - - - Vested (RSUs) - - (1,167,473 ) 2.88 (403,422 ) 2.11 Cancelled/Forfeited (652,555 ) 4.24 (72,655 ) 3.67 (6,179 ) 2.98 Performance Factor Adjustment - - - - 163,216 2.98 Balance at December 31, 2021 1,404,816 $ 3.10 1,141,164 $ 3.57 860,155 $ 3.13 Granted - - 918,870 4.64 320,272 5.08 Exercised (40,267 ) 2.64 - - - - Vested (RSUs) - - (733,611 ) 4.08 (401,308 ) 2.11 Cancelled/Forfeited (125,773 ) 2.77 (232,622 ) 4.44 (132,884 ) 4.21 Balance at December 31, 2022 1,238,776 $ 3.15 1,093,801 $ 3.94 646,235 $ 4.51
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Weighted average shares outstanding - basic 41,413 40,343 Dilutive effect of equity awards - - Weighted average shares outstanding - diluted 41,413 40,343 Shares excluded from diluted loss per share due to their anti-dilutive effect 3,661 4,274
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Weighted Average Weighted Average Weighted Range of Remaining Average Aggregate Remaining Average Aggregate Exercise Number Contractual Life Exercise Intrinsic Shares Contractual Life Exercise Intrinsic Price Outstanding in Years Price Value Exercisable in Years Price Value $ 1.78 - 2.62 135,342 6.3 $ 1.89 $ 119 102,381 6.2 $ 1.91 $ 88 2.63 - 2.78 505,423 4.4 2.63 71 357,192 4.4 2.63 50 2.79 - 3.24 135,077 6.6 2.93 - 135,077 6.6 2.93 - 3.25 - 3.72 206,808 4.2 3.38 - 206,808 4.2 3.38 - 3.73 - 5.51 256,126 3.2 4.76 - 238,222 3.0 4.83 - $ 1.78 - 5.51 1,238,776 4.6 $ 3.15 $ 190 1,039,680 4.5 $ 3.25 $ 138
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Cost of revenues $ 121 $ 118 Sales and marketing expenses 557 507 General and administrative expenses 3,487 3,416 Research and development expenses 246 128 Total stock-based compensation expenses $ 4,411 $ 4,169
Black Scholes Option Pricing Model [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2022 2021 Volatility 62.6 % 65.1 % Risk-free interest rate 2.1 % 0.3 % Correlation coefficient 41.5 % 35.7 % Dividend yield - % - %

Note 11 - Long-term Debt (Table

Note 11 - Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Debt [Table Text Block]	December 31, December 31, (in thousands) 2022 2021 Long-term debt: Term loan $ 34,814 $ 38,000 Revolving line 12,850 11,450 Less: unamortized deferred financing costs (840 ) (1,120 ) Total debt 46,824 48,330 Less: current installments (4,091 ) (3,515 ) Current unamortized deferred financing costs 280 280 Long-term debt $ 43,013 $ 45,095
Schedule of Maturities of Long-Term Debt [Table Text Block]	(in thousands) 2023 $ 4,091 2024 4,000 2025 39,573 $ 47,664

Note 12 - Revenues (Tables)

Note 12 - Revenues (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Instruments, equipment, software and accessories $ 108,165 $ 114,115 Service, maintenance and warranty contracts 5,170 4,789 Total revenues $ 113,335 $ 118,904
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	December 31, (in thousands) 2022 2021 Service contracts $ 1,530 $ 1,976 Customer advances 1,840 2,290 Total deferred revenue $ 3,370 $ 4,266
Financing Receivable, Allowance for Credit Loss [Table Text Block]	December 31, (in thousands) 2022 2021 Balance, beginning of period $ 136 $ 227 Bad debt expense (credit) 62 (4 ) Charge-offs and other (7 ) (87 ) Balance, end of period $ 191 $ 136
Schedule of Product Warranty Liability [Table Text Block]	December 31, (in thousands) 2022 2021 Balance, beginning of period $ 240 $ 186 Expense 408 319 (Charges)/Credits (380 ) (265 ) Balance, end of period $ 268 $ 240

Note 13 - Income Tax (Tables)

Note 13 - Income Tax (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Current income tax expense: Federal and state $ 641 $ 363 Foreign 194 156 835 519 Deferred income tax (benefit) expense: Federal and state (468 ) 22 Foreign (30 ) (393 ) (498 ) (371 ) Total income tax expense $ 337 $ 148
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Provision for income taxes at federal statutory rates $ (1,927 ) $ (29 ) Increase (decrease) in income taxes resulting from: Permanent differences, net 375 (362 ) Non-deductible executive compensation 346 412 Global Intangible Low-Taxed Income (GILTI) 552 - Foreign tax rate differential (103 ) (217 ) State income taxes, net of federal income tax benefit (295 ) (16 ) Non-deductible stock compensation expense 69 280 Tax credits 492 455 Net operating loss true-ups and expirations 431 195 Change in reserve for uncertain tax position 688 (118 ) Impact of change to prior year tax accruals (232 ) 269 Change in valuation allowance allocated to income tax (102 ) (961 ) Other 43 240 Total income tax expense $ 337 $ 148
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Domestic $ (9,099 ) $ 2,364 Foreign (80 ) (2,504 ) Total $ (9,179 ) $ (140 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 Deferred income tax assets: Inventory $ 1,696 $ 1,280 Operating loss and credit carryforwards 14,883 18,046 Accrued expenses 621 835 Deferred interest expense 881 1,191 Stock compensation 675 580 Lease liability 1,538 1,693 Research and development 2,000 - Other assets 726 386 Total gross deferred assets 23,020 24,011 Less: valuation allowance (14,506 ) (14,700 ) Deferred tax assets $ 8,514 $ 9,311 Deferred income tax liabilities: Indefinite-lived intangible assets $ 1,914 $ 1,882 Definite-lived intangible assets 4,875 6,277 Right-of-use asset 1,148 1,277 Other liabilities 834 1,228 Total deferred tax liabilities 8,771 10,664 Deferred income tax liability, net $ (257 ) $ (1,353 ) Year Ended December 31, (in thousands) 2022 2021 Deferred tax assets (included in other long-term assets) $ 333 $ 205 Deferred income tax liabilities (590 ) (1,558 ) Deferred income tax liability, net $ (257 ) $ (1,353 )
Summary of Income Tax Contingencies [Table Text Block]	(in thousands) Balance at December 31, 2020 $ 1,673 Decreases based on tax positions of prior years (208 ) Additions based on tax positions of current years 176 Decreases based on expiration of statutes of limitation (42 ) Settlements and other (267 ) Balance at December 31, 2021 1,332 Additions based on tax positions of prior years 534 Decreases based on tax positions of prior years (34 ) Additions based on tax positions of current years 237 Decreases based on expiration of statutes of limitation (86 ) Balance at December 31, 2022 $ 1,983

Note 16 - Segment and Related_2

Note 16 - Segment and Related Information (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, (in thousands) 2022 2021 United States $ 49,912 $ 49,831 Europe 30,687 35,767 Greater China 16,393 13,496 Rest of the world 16,343 19,810 Total revenues $ 113,335 $ 118,904
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	December 31, (in thousands) 2022 2021 United States $ 26,051 $ 31,512 Germany 2,432 3,501 Rest of the world 1,489 2,446 Total long-lived assets $ 29,972 $ 37,459
Schedule of Net Assets By Geographic Areas [Table Text Block]	December 31, (in thousands) 2022 2021 United States $ 34,408 $ 38,641 Germany 14,761 15,501 United Kingdom 10,116 13,999 Rest of the world 12,935 15,260 Total net assets $ 72,220 $ 83,401

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands		12 Months Ended
	Jun. 10, 2022 USD ($) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Cash and Cash Equivalents, at Carrying Value, Total		$ 4,508	$ 7,821
Percentage of Cash and Cash Equivalents Held by Foreign Subsidiaries		56%
Number of Reporting Units		1
Goodwill, Impairment Loss		$ 0
Impairment of Long-Lived Assets Held-for-use		0
Series E Preferred Stock in Biostage [Member]
Stock Issued During Period, Value, Issued for Settlement		$ 3,900
Case in Suffolk Superior Court [Member] | Contingent Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Issued For Settlement (in shares) | shares	4,000
Stock Issued During Period, Value, Issued for Settlement	$ 4,000
Minimum [Member]
Customer Payments Term (Day)		0 days
Finite-Lived Intangible Asset, Useful Life (Year)		4 years
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		1 year
Maximum [Member]
Customer Payments Term (Day)		60 days
Finite-Lived Intangible Asset, Useful Life (Year)		15 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		4 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Machinery and Equipment [Member] | Minimum [Member]
Property, plant and equipment useful life (Year)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, plant and equipment useful life (Year)	10 years
Computer Equipment and Software [member] | Minimum [Member]
Property, plant and equipment useful life (Year)	3 years
Computer Equipment and Software [member] | Maximum [Member]
Property, plant and equipment useful life (Year)	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, plant and equipment useful life (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, plant and equipment useful life (Year)	10 years

Note 3 - Accumulated Other Co_3

Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 83,401	$ 76,681
Other comprehensive (loss) income	(5,025)	3,039
Balance	72,220	83,401
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(13,826)	(11,473)
Other comprehensive income (loss) before reclassifications	(2,960)	(2,353)
Amounts reclassified from AOCI	0	0
Other comprehensive (loss) income	(2,960)	(2,353)
Balance	(16,786)	(13,826)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Balance	3,799	(1,593)
Other comprehensive income (loss) before reclassifications	(2,085)	4,946
Amounts reclassified from AOCI	20	446
Other comprehensive (loss) income	(2,065)	5,392
Balance	1,734	3,799
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	(10,027)	(13,066)
Other comprehensive income (loss) before reclassifications	(5,046)	2,593
Amounts reclassified from AOCI	20	446
Other comprehensive (loss) income	(5,025)	3,039
Balance	$ (15,052)	$ (10,027)

Note 4 - Goodwill and Intangi_3

Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fully Amortized Intangible Assets Related to Customer Relationships and Discontinued Product Lines	$ 2,500
Amortization of Intangible Assets	$ 6,122	$ 5,840

Note 4 - Goodwill and Intangi_4

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Carrying amount	$ 57,689	$ 58,590
Effect of change in currency translation	(1,429)	(901)
Carrying amount	$ 56,260	$ 57,689

Note 4 - Goodwill and Intangi_5

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Gross		$ 61,196	$ 64,892
Total amortizable intangible assets		(40,406)	(37,745)
Finite-Lived Intangible Assets, Net		20,790	27,147
Indefinite-lived intangible assets:		224	238
Total intangible assets, Net		$ 21,014	27,385
Distribution Agreements/Customer Relationships [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	7 years 2 months 12 days
Finite-Lived Intangible Assets, Gross		$ 16,124	17,689
Total amortizable intangible assets		(8,727)	(8,675)
Finite-Lived Intangible Assets, Net		$ 7,397	9,014
Existing Technology [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	3 years 2 months 12 days
Finite-Lived Intangible Assets, Gross		$ 37,549	38,707
Total amortizable intangible assets		(26,482)	(23,962)
Finite-Lived Intangible Assets, Net		$ 11,067	14,745
Trade Names and Patents [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	3 years 8 months 12 days
Finite-Lived Intangible Assets, Gross		$ 7,523	8,496
Total amortizable intangible assets		(5,197)	(5,108)
Finite-Lived Intangible Assets, Net		$ 2,326	$ 3,388
[1]Weighted average life in years as of September 30, 2022

Note 4 - Goodwill and Intangi_6

Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 5,546
2024	5,248
2025	4,020
2026	2,359
2027	1,262
Thereafter	2,355
Total	$ 20,790	$ 27,147

Note 5 - Balance Sheet Inform_3

Note 5 - Balance Sheet Information (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Fully Depreciated and Disposed of Property and Equipment Removed From Fixed Asset Records	$ 0.7

Note 5 - Balance Sheet Inform_4

Note 5 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finished goods	$ 5,223	$ 5,646
Work in process	3,776	3,410
Raw materials	17,440	18,531
Total	$ 26,439	$ 27,587

Note 5 - Balance Sheet Inform_5

Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment, Gross	$ 18,212	$ 17,864
Less: accumulated depreciation	(14,846)	(14,449)
Property, plant and equipment, net	3,366	3,415
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross	7,500	7,698
Computer Equipment and Software [member]
Property, Plant and Equipment, Gross	6,781	6,269
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	2,507	2,560
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	1,386	1,296
Automobiles [Member]
Property, Plant and Equipment, Gross	$ 38	$ 41

Note 5 - Balance Sheet Inform_6

Note 5 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Compensation	$ 3,476	$ 6,048
Professional fees	392	480
Warranty costs	268	240
Customer advances	2,368	2,265
Accrued income taxes	0	224
Other	982	1,505
Total	$ 7,486	$ 10,762

Note 6 - Restructuring and Ot_3

Note 6 - Restructuring and Other Exit Costs (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Restructuring Charges, Total	$ 2,394	$ 1,275
Cost of Sales [Member]
Restructuring Charges, Total	1,500
General and Administrative Expense [Member]
Restructuring Charges, Total	$ 900

Note 6 - Restructuring and Ot_4

Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 0	$ 288
Restructuring and other exit costs	2,394	1,275
Non-cash charges	(1,471)	(46)
Cash payments	(287)	(1,517)
Balance	636	0
Cost of Revenues [Member]
Balance	0	0
Restructuring and other exit costs	1,471	0
Non-cash charges	(1,471)	0
Cash payments	0	0
Balance	0	0
Employee Severance [Member]
Balance	0	270
Restructuring and other exit costs	877	1,174
Non-cash charges	0	0
Cash payments	(241)	(1,444)
Balance	636	0
Other Restructuring [Member]
Balance	0	18
Restructuring and other exit costs	46	101
Non-cash charges	0	(46)
Cash payments	(46)	(73)
Balance	$ 0	$ 0

Note 7 - Related Party Transa_2

Note 7 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
The Multi Channel Systems Facility and Triangle BioSystems Lease Agreements [Member]
Operating Lease, Expense	$ 0.3	$ 0.3

Note 8 - Employee Benefit Pla_3

Note 8 - Employee Benefit Plans (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan, Cost	$ 1.1	$ 1
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	0.6
Defined Benefit Plan, Expected Future Benefit Payment, Year One	0.7
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	0.7
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	0.8
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	0.9
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	0.7
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years	$ 4.5

Note 8 - Employee Benefit Pla_4

Note 8 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Interest cost	$ 371	$ 358
Expected return on plan assets	(818)	(675)
Net amortization loss	27	551
Recognition of net loss due to settlements	0	115
Net periodic benefit (credit) cost	$ (420)	$ 349

Note 8 - Employee Benefit Pla_5

Note 8 - Employee Benefit Plans - Change in Benefit Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan, Benefit Obligation, Balance	$ 22,562	$ 25,519
Interest cost	371	358
Actuarial (gain) loss	(6,912)	(2,440)
Settlements due to transfers paid	0	(198)
Benefits paid	(592)	(498)
Currency translation adjustment	(2,166)	(179)
Defined Benefit Plan, Benefit Obligation, Balance	$ 13,263	$ 22,562

Note 8 - Employee Benefit Pla_6

Note 8 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan, Fair Value of Plan Assets, Balance	$ 27,252	$ 23,926
Actual return on plan assets	(9,098)	3,354
Employer contributions	619	1,042
Settlement due to transfers paid	0	(270)
Benefits paid	(592)	(498)
Currency translation adjustment	(2,605)	(302)
Defined Benefit Plan, Fair Value of Plan Assets, Balance	$ 15,576	$ 27,252

Note 8 - Employee Benefit Pla_7

Note 8 - Employee Benefit Plans - Change in Benefit Obligation (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Benefit obligation	$ 13,263	$ 22,562	$ 25,519
Fair value of plan assets	15,576	27,252	$ 23,926
Net funded status	1,734	3,799
Pension Plan [Member]
Benefit obligation	13,263	22,562
Fair value of plan assets	15,576	27,252
Net funded status	$ 2,313	$ 4,690

Note 8 - Employee Benefit Pla_8

Note 8 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other long-term assets	$ 1,734	$ 3,799
Other Noncurrent Liabilities [Member]
Other long-term assets	2,313	4,690
Deferred Tax Liability [Member]
Other long-term assets	$ (579)	$ (891)

Note 8 - Employee Benefit Pla_9

Note 8 - Employee Benefit Plans - Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Discount rate	5%	1.80%
Expected return on assets	5%	2.80%

Note 8 - Employee Benefit Pl_10

Note 8 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair value of plan assets		$ 15,576	$ 27,252	$ 23,926
Defined Benefit Plan, Actual Plan Asset Allocations		100%	100%
Defined Benefit Plan, Equity Securities [Member]
Fair value of plan assets		$ 3,507	$ 14,295
Defined Benefit Plan, Actual Plan Asset Allocations		23%	52%
Debt Security, Corporate, US [Member]
Fair value of plan assets	[1]	$ 11,714	$ 4,720
Defined Benefit Plan, Actual Plan Asset Allocations		75%	17%
Liability Driven Investment Funds [Member]
Fair value of plan assets		$ 0	$ 5,722
Defined Benefit Plan, Actual Plan Asset Allocations		0%	21%
Defined Benefit Plan, Cash and Cash Equivalents [Member]
Fair value of plan assets		$ 185	$ 1,907
Defined Benefit Plan, Actual Plan Asset Allocations		1%	7%
Other Plan Assets [Member]
Fair value of plan assets		$ 170	$ 608
Defined Benefit Plan, Actual Plan Asset Allocations		1%	2%
[1]Updated dimension from: "Debt Securities [Member]".

Note 8 - Employee Benefit Pl_11

Note 8 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair value of plan assets	$ 15,576	$ 27,252	$ 23,926
Fair Value, Inputs, Level 1 [Member]
Fair value of plan assets	185	1,907
Fair Value, Inputs, Level 2 [Member]
Fair value of plan assets	15,391	25,345
Fair Value, Inputs, Level 3 [Member]
Fair value of plan assets	$ 0	$ 0

Note 9 - Leases - Lease Expense

Note 9 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating lease cost	$ 1,971	$ 2,041
Short-term lease cost	233	196
Sublease income	(102)	(102)
Total lease cost	$ 2,102	$ 2,135

Note 9- Leases - Supplemental C

Note 9- Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:	$ 2,347	$ 2,365
Right-of-use assets obtained in exchange for lease obligations:	$ 295	$ 524

Note 9 - Leases - Supplemental

Note 9 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating lease right-of-use assets	$ 5,816	$ 6,897
Current portion, operating lease liabilities	2,135	2,142
Operating lease liabilities, long-term	5,282	6,488
Total operating lease liabilities	$ 7,417	$ 8,630
Weighted average remaining lease term (years) (Year)	6 years 2 months 12 days	6 years 8 months 12 days
Weighted average discount rate	9.40%	9.30%

Note 9 - Leases - Future Minimu

Note 9 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 2,135
2024	1,794
2025	1,064
2026	1,022
2027	1,004
Thereafter	2,995
Total lease payments	10,014
Less imputed interest	(2,597)
Total operating lease liabilities	$ 7,417	$ 8,630

Note 10 - Capital Stock and S_3

Note 10 - Capital Stock and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	May 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Treasury Stock, Shares, Retired (in shares)	7,800,000
Preferred Stock, Shares Authorized (in shares)		5,000,000	5,000,000
Employee Stock Purchase Plan, Consecutive Payment Periods (Year)		6 years
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date		85%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)		200,000	100,000
Share Price (in dollars per share)		$ 2.77
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 0.1	$ 1.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 5.1
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 7 months 6 days
Market Condition Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Factor Adjustment (in shares)		163,216	163,216
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		401,308	403,422
Minimum Vesting Rate of the Targeted Shareholder Return, Percentage		0%
Maximum Vesting Rate of the Targeted Shareholder Return, Percentage		150%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 5.08	$ 4.61
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		1 year
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		400,000
2021 Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		3,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		2,100,000

Note 10 - Capital Stock and S_4

Note 10 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Opening Balance, Stock Options Outstanding (in shares)	1,404,816	2,637,339
Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.10	$ 3.51
Options, Granted in Period (in shares)	0	0
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share)	$ 0	$ 0
Options, exercised (in shares)	(40,267)	(579,968)
Options, exercised, weighted average exercise price (in dollars per share)	$ 2.64	$ 3.77
Options, Cancelled / Forfeited in Period (in shares)	(125,773)	(652,555)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share)	$ 2.77	$ 4.24
Opening Balance, Stock Options Outstanding (in shares)	1,238,776	1,404,816
Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.15	$ 3.10
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units Outstanding , Balance (in shares)	1,141,164	1,560,461
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 3.57	$ 2.44
Restricted Stock Units, Granted in Period (in shares)	918,870	820,831
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share)	$ 4.64	$ 4.74
Restricted Stock Units, Vested in Period (in shares)	(733,611)	(1,167,473)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share)	$ 4.08	$ 2.88
Restricted Stock Units, Cancelled / Forfeited in Period (in shares)	(232,622)	(72,655)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share)	$ 4.44	$ 3.67
Performance Factor Adjustment (in shares)		0
Performance Factor Adjustment, grant date fair value (in dollars per share)		$ 0
Restricted Stock Units Outstanding , Balance (in shares)	1,093,801	1,141,164
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 3.94	$ 3.57
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares)	860,155	813,031
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 3.13	$ 2.12
Restricted Stock Units, Granted in Period (in shares)	320,272	293,509
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share)	$ 5.08	$ 4.61
Restricted Stock Units, Vested in Period (in shares)	(401,308)	(403,422)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share)	$ 2.11	$ 2.11
Restricted Stock Units, Cancelled / Forfeited in Period (in shares)	(132,884)	(6,179)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share)	$ 4.21	$ 2.98
Performance Factor Adjustment (in shares)	163,216	163,216
Performance Factor Adjustment, grant date fair value (in dollars per share)		$ 2.98
Restricted Stock Units Outstanding , Balance (in shares)	646,235	860,155
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 4.51	$ 3.13

Note 10 - Capital Stock and S_5

Note 10 - Capital Stock and Stock-based Compensation - Earnings (Loss) Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Weighted average shares outstanding - basic (in shares)	41,413	40,343
Dilutive effect of equity awards (in shares)	0	0
Weighted average shares outstanding - diluted (in shares)	41,413	40,343
Shares excluded from diluted loss per share due to their anti-dilutive effect (in shares)	3,661	4,274

Note 10 - Capital Stock and S_6

Note 10 - Capital Stock and Stock-based Compensation - Outstanding and Exercisable Options (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Range of Exercise Price, Lower Limit (in dollars per share)	$ 1.78
Range of Exercise Price, Upper Limit (in dollars per share)	$ 5.51
Options Outstanding, Shares Outstanding (in shares) | shares	1,238,776
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	4 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.15
Options Outstanding, Aggregate Intrinsic Value | $	$ 190
Options Exercisable, Shares Exercisable (in shares) | shares	1,039,680
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	4 years 6 months
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.25
Options Exercisable, Aggregate Intrinsic Value | $	$ 138
Exercise Price Range 1 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 1.78
Range of Exercise Price, Upper Limit (in dollars per share)	$ 2.62
Options Outstanding, Shares Outstanding (in shares) | shares	135,342
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	6 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 1.89
Options Outstanding, Aggregate Intrinsic Value | $	$ 119
Options Exercisable, Shares Exercisable (in shares) | shares	102,381
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	6 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 1.91
Options Exercisable, Aggregate Intrinsic Value | $	$ 88
Exercise Price Range 2 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 2.63
Range of Exercise Price, Upper Limit (in dollars per share)	$ 2.78
Options Outstanding, Shares Outstanding (in shares) | shares	505,423
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	4 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.63
Options Outstanding, Aggregate Intrinsic Value | $	$ 71
Options Exercisable, Shares Exercisable (in shares) | shares	357,192
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	4 years 4 months 24 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 2.63
Options Exercisable, Aggregate Intrinsic Value | $	$ 50
Exercise Price Range 3 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 2.79
Range of Exercise Price, Upper Limit (in dollars per share)	$ 3.24
Options Outstanding, Shares Outstanding (in shares) | shares	135,077
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	6 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.93
Options Outstanding, Aggregate Intrinsic Value | $	$ 0
Options Exercisable, Shares Exercisable (in shares) | shares	135,077
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	6 years 7 months 6 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 2.93
Options Exercisable, Aggregate Intrinsic Value | $	$ 0
Exercise Price Range 4 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 3.25
Range of Exercise Price, Upper Limit (in dollars per share)	$ 3.72
Options Outstanding, Shares Outstanding (in shares) | shares	206,808
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	4 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.38
Options Outstanding, Aggregate Intrinsic Value | $	$ 0
Options Exercisable, Shares Exercisable (in shares) | shares	206,808
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	4 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.38
Options Exercisable, Aggregate Intrinsic Value | $	$ 0
Exercise Price Range 5 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 3.73
Range of Exercise Price, Upper Limit (in dollars per share)	$ 5.51
Options Outstanding, Shares Outstanding (in shares) | shares	256,126
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	3 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.76
Options Outstanding, Aggregate Intrinsic Value | $	$ 0
Options Exercisable, Shares Exercisable (in shares) | shares	238,222
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	3 years
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.83
Options Exercisable, Aggregate Intrinsic Value | $	$ 0

Note 10 - Capital Stock and S_7

Note 10 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based compensation	$ 4,411	$ 4,169
Continuing Operations [Member] | Cost of Sales [Member]
Share-based compensation	121	118
Continuing Operations [Member] | Selling and Marketing Expense [Member]
Share-based compensation	557	507
Continuing Operations [Member] | General and Administrative Expense [Member]
Share-based compensation	3,487	3,416
Continuing Operations [Member] | Research and Development Expense [Member]
Share-based compensation	$ 246	$ 128

Note 10 - Capital Stock and S_8

Note 10 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member] - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Volatility	62.60%	65.10%
Risk-free interest rate	2.10%	0.30%
Correlation coefficient	41.50%	35.70%
Dividend yield	0%	0%

Note 11 - Long-term Debt (Detai

Note 11 - Long-term Debt (Details Textual) - USD ($) $ in Thousands			12 Months Ended
	Nov. 08, 2022	Apr. 28, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 22, 2020
Long-term Debt, Gross			$ 47,664
Debt Issuance Costs, Net, Total			$ 840	$ 1,120
The Credit Agreement [Member]
Debt Issuance Costs, Net, Total						$ 1,400
Line of Credit Facility, Interest Rate During Period			5%	3.30%
Line of Credit Facility, Interest Rate at Period End			7.60%
Debt Instrument, Quarterly Payment, Current Year					$ 500
Debt Instrument Quarterly Payment Next Eight Years					750
Debt Instrument, Quarterly Payment, Thereafter					$ 1,000
Percentage of Consolidated Excess Cash Flow					50%
Debt Instrument, Current Maturities, Excess Cash Flow Sweep			$ 1,100
Payments of Debt Restructuring Costs		$ 200
Payments for Debt Fees	$ 200
The Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Interest Rate, State Floor Percentage			0.50%
The Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate			3.25%
The Credit Agreement [Member] | Base Rate [Member]
Debt Instrument, Interest Rate, State Floor Percentage			1%
The Credit Agreement [Member] | The ABR Loan [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			1.50%
The Credit Agreement [Member] | The ABR Loan [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate			3%
The Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Remaining Borrowing Capacity			$ 2,900
Term Loan [Member]
Long-term Debt, Gross			$ 34,814	$ 38,000
The LIBOR Loan and Pricing Grid Credit Agreement [Member] | The Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			2%
The Lenders [Member] | The Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						25,000
The Lenders [Member] | The Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity						10,000
The Lenders [Member] | The Credit Agreement [Member] | Swingline Loan Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						10,000
The Lenders [Member] | Term Loan [Member] | The Credit Agreement [Member]
Long-term Debt, Gross						$ 40,000

Note 11 - Long-term Debt - Brea

Note 11 - Long-term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Long-term debt, gross	$ 47,664
Less: unamortized deferred financing costs	(840)	$ (1,120)
Total debt	46,824	48,330
Less: current installments	(4,091)	(3,515)
Current unamortized deferred financing costs	280	280
Long-term debt	43,013	45,095
Term Loan [Member]
Long-term debt, gross	34,814	38,000
Line of Credit [Member]
Long-term debt, gross	$ 12,850	$ 11,450

Note 11 - Long Term Debt - Debt

Note 11 - Long Term Debt - Debt Maturity (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 4,091
2024	4,000
2025	39,573
Total	$ 47,664

Note 12 - Revenues (Details Tex

Note 12 - Revenues (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Contract with Customer, Liability, Revenue Recognized	$ 2.5	$ 2

Note 12 - Revenues - Disaggrega

Note 12 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues	$ 113,335	$ 118,904
Instruments, Equipment, Software, and Accessories [Member]
Revenues	108,165	114,115
Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 5,170	$ 4,789

Note 12 - Revenues - Deferred R

Note 12 - Revenues - Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred revenue	$ 3,370	$ 4,266
Service [Member]
Deferred revenue	1,530	1,976
Customer Advances [Member]
Deferred revenue	$ 1,840	$ 2,290

Note 12 - Revenues - Allowance

Note 12 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance, beginning of period	$ 136	$ 227
Bad debt expense (credit)	62	(4)
Charge-offs and other	(7)	(87)
Balance, end of period	$ 191	$ 136

Note 12 - Revenues - Warranties

Note 12 - Revenues - Warranties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 240	$ 186
Expense	408	319
(Charges)/Credits	(380)	(265)
Balance	$ 268	$ 240

Note 13 - Income Tax (Details T

Note 13 - Income Tax (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, Percent, Total	(3.70%)	(105.70%)
Deferred Tax Assets, Valuation Allowance	$ 14,506	$ 14,700
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(200)	(2,000)
Research and Development Tax Credit Carryforwards Offset by Reserve for Uncertain Tax Positions	800
Deferred Tax Assets, Tax Credit Carryforwards, Total	2,700
Cash and Cash Equivalents, at Carrying Value, Total	4,508	7,821
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	2,000
Non-US [Member] | Subsidiaries [Member]
Cash and Cash Equivalents, at Carrying Value, Total	2,600	2,800
Expire 2023 [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	8,100
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	100
Expire 2036 [Member] | Research Tax Credit Carryforward [Member]
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	$ 200
Domestic Tax Authority [Member]
Open Tax Year	2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	$ 13,400
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Expire between 2029 and 2038 [Member]
Operating Loss Carryforwards	13,300
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Indefinite Carryforward Beyond 2038 [Member]
Operating Loss Carryforwards	100
State and Local Jurisdiction [Member] | Expire between 2023 and 2042 [Member]
Operating Loss Carryforwards	9,600
Foreign Tax Authority [Member]
Operating Loss Carryforwards	$ 8,000
Open Tax Year	2018 2019 2020 2021 2022
UK Pension Liability [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ (900)

Note 13 - Income Tax - Income T

Note 13 - Income Tax - Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Federal and state	$ 641	$ 363
Foreign	194	156
current income tax (benefit) expense	835	519
Federal and state	(468)	22
Foreign	(30)	(393)
deferred income tax (benefit) expense	(498)	(371)
Total income tax expense	$ 337	$ 148

Note 13 - Income Tax - Income_2

Note 13 - Income Tax - Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Provision for income taxes at federal statutory rates	$ (1,927)	$ (29)
Permanent differences, net, amount	375	(362)
Non-deductible executive compensation	346	412
Global Intangible Low-Taxed Income (GILTI)	552	0
Foreign tax rate differential	(103)	(217)
State income taxes, net of federal income tax benefit, amount	(295)	(16)
Non-deductible stock compensation expense, amount	69	280
Tax credits	492	455
Net operating loss true-ups and expirations	431	195
Change in reserve for uncertain tax position	688	(118)
Impact of change to prior year tax accruals	(232)	269
Change in valuation allowance allocated to income tax	(102)	(961)
Other	43	240
Total income tax expense (benefit)	$ 337	$ 148

Note 13 - Income Tax - Pre-tax

Note 13 - Income Tax - Pre-tax Income From Continuing Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Domestic	$ (9,099)	$ 2,364
Foreign	(80)	(2,504)
Total	$ (9,179)	$ (140)

Note 13 - Income Tax - Deferred

Note 13 - Income Tax - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory	$ 1,696	$ 1,280
Operating loss and credit carryforwards	14,883	18,046
Accrued expenses	621	835
Deferred interest expense	881	1,191
Stock compensation	675	580
Lease liability	1,538	1,693
Research and development	2,000	0
Other assets	726	386
Total gross deferred assets	23,020	24,011
Less: valuation allowance	(14,506)	(14,700)
Deferred tax assets	8,514	9,311
Indefinite-lived intangible assets	1,914	1,882
Definite-lived intangible assets	4,875	6,277
Right-of-use asset	1,148	1,277
Other liabilities	834	1,228
Total deferred tax liabilities	8,771	10,664
Deferred income tax liability, net	(257)	(1,353)
Deferred tax assets (included in other long-term assets)	333	205
Deferred income tax liabilities	$ (590)	$ (1,558)

Note 13 - Income Tax - Unrecogn

Note 13 - Income Tax - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 1,332	$ 1,673
Decreases based on tax positions of prior years	(34)	(208)
Additions based on tax positions of current years	237	176
Decreases based on expiration of statutes of limitation	(86)	(42)
Settlements and other		(267)
Additions based on tax positions of prior years	534
Balance	$ 1,983	$ 1,332

Note 14 - Commitments and Con_2

Note 14 - Commitments and Contingent Liabilities (Details Textual) $ in Thousands	Dec. 31, 2022 USD ($)
Director [Member] | Indemnification Agreements [Member]
Liability for Contingent Indemnification Obligations	$ 0

Note 15 - Litigation Settleme_2

Note 15 - Litigation Settlement (Details Textual) - USD ($)		3 Months Ended	12 Months Ended
	Jun. 10, 2022	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Mar. 31, 2022
Litigation Settlement, Expense			$ (233,000)	$ 0
Series E Preferred Stock in Biostage [Member]
Stock Issued During Period, Value, Issued for Settlement			3,900,000
Equity Securities without Readily Determinable Fair Value, Amount	$ 3,900,000
Preferred Stock, Book Value, Inclusive of Accrued Dividends			$ 4,100,000
Convertible Preferred Stock [Member] | Biostage [Member]
Preferred Stock, Dividend Rate, Percentage			8%
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 1,000
Preferred Stock, Mandatory Conversion, Minimum Qualified Offering Amount			$ 4,000,000
Case in Suffolk Superior Court [Member]
Loss Contingency, Estimate of Possible Loss						$ 5,200,000
Legal Fees				$ 300,000
Litigation Settlement, Expense		$ (4,900,000)
Case in Suffolk Superior Court [Member] | Convertible Preferred Stock [Member]
Estimated Litigation Liability					$ 500,000
Stock Issued During Period, Shares, Issued For Settlement (in shares)	4,000
Stock Issued During Period, Value, Issued for Settlement	$ 4,000,000

Note 16 - Segment and Related_3

Note 16 - Segment and Related Information (Details Textual)	12 Months Ended
	Dec. 31, 2022
Number of Operating Segments	1

Note 16 - Segment and Related_4

Note 16 - Segment and Related Information - Revenue by Geographic Destination (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total revenues	$ 113,335	$ 118,904
UNITED STATES
Total revenues	49,912	49,831
Europe [Member]
Total revenues	30,687	35,767
Greater China [Member]
Total revenues	16,393	13,496
Rest of the World [Member]
Total revenues	$ 16,343	$ 19,810

Note 16 - Segment and Related_5

Note 16 - Segment and Related Information - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Total long-lived assets	[1]	$ 29,972	$ 37,459
UNITED STATES | Continuing Operations [Member]
Total long-lived assets		26,051	31,512
GERMANY | Continuing Operations [Member]
Total long-lived assets		2,432	3,501
Rest of the World [Member] | Continuing Operations [Member]
Total long-lived assets		$ 1,489	$ 2,446
[1]consists of operating lease right-of-use assets, property, plant and equipment, net and amortizable intangible assets, net.

Note 16 - Segment and Related_6

Note 16 - Segment and Related Information - Net Assets by Geographic Area (Details) - Continuing Operations [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Total net assets	$ 72,220	$ 83,401
UNITED STATES
Total net assets	34,408	38,641
GERMANY
Total net assets	14,761	15,501
UNITED KINGDOM
Total net assets	10,116	13,999
Rest of the World [Member]
Total net assets	$ 12,935	$ 15,260

Note 17 - Government Assistan_2

Note 17 - Government Assistance (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Programs Established to Offset the Impact of COVID [Member]
Government Assistance, Amount	$ 0.7

Note 18 - Subsequent Event - _2

Note 18 - Subsequent Event - Derivatives (Details Textual) - Subsequent Event [Member] $ in Millions	Feb. 28, 2023 USD ($)
The Credit Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Interest Rate Swap [Member]
Derivative, Notional Amount	$ 33.4